Molecular diagnostics portfolio including EndoPredict — a genomic test that predicts recurrence risk and chemotherapy benefit for ER+, HER2− early-stage breast cancer to support adjuvant treatment decisions. Prolaris Kits — a prognostic prostate cancer test measuring cell-cycle gene expression to assess tumor aggressiveness, enable risk stratification and guide personalized treatment.